

Index

A

- AAA-ATPase, 61
- ACAT1, 268, 285–286
- ACAT2, 83, 268, 286
- ACBD4, 246
- ACBD5, 246
- ACSL1, 262
- ACSL3, 262
- ACSL4, 262
- AD. *See* Alzheimer's disease
- ADAM17. *See* TACE
- AGPAT2, 265
- ALADIN, 343
- ALG2, 186
- ALOD4, 278, 284–285
- AlphaFold, 230–232
- ALS. *See* Amyotrophic lateral sclerosis
- Alzheimer's disease (AD), RHBDL4 role, 105
- AMFR, 66, 83
- AMPylation. *See* BiP; FICD
- Amyloid precursor protein (APP), 105
- Amyotrophic lateral sclerosis (ALS), 244–246
- ANE1, 346
- APOB. *See* Apolipoprotein B
- Apolipoprotein B (APOB)
 - assembly and lipidation, 197–198
 - endocytosis and human disease, 198–199
 - genetics of lipoprotein secretion, 199–200
 - glycerolipid synthesis in endoplasmic reticulum, 270–271
 - overview of COPII lipoprotein secretion, 197
 - prospects for study, 203–204
- APP. *See* Amyloid precursor protein
- Apratoxin A, 11
- ARH, 199
- ARL61P1, 303
- Asi1, 66, 82
- Asi2, 65–66, 82
- Asi3, 66, 82
- Asi complex, 64, 82–83
- ASK1, 135
- Aster-A, 280–282, 285
- Aster-B, 280–282, 285–286, 288
- Aster-C, 282, 285–286
- Asterix, 29, 31
- ATAD1, 61, 64
- ATF4, 324
- ATF6
 - ATF6-like factors in vertebrates, 132
 - knockout studies, 133
 - unfolded protein response pathway, 130–131
- Atg1, 221
- ATG2
 - Atg18 complex, 228
 - defects and neurodegenerative disease, 251
 - ER-phagy, 216
 - lipid transport to isolation membrane
 - lipid specificity, 229
 - structural basis of lipid transfer, 230–232
 - transfer rates of lipids, 229–230
 - structure, 230–232
 - WIPI4 complex, 229
- ATG2A, 251
- ATG2B, 251
- ATG3, 214
- ATG5, 214
- ATG7, 221
- Atg7, 221
- ATG8, 214, 220
- Atg8, 214, 221, 228
- ATG9, 218, 221
- Atg9, 228, 232–234, 236–237
- ATG9A, 232–234, 237
- Atg12, 228
- ATG13, 214, 218, 221
- ATG14, 221
- Atg14, 221
- Atg16, 221
- ATG18, 251
- Atg18, 228
- Atg39, 214–215, 220–221
- Atg40, 214–215, 219, 221
- ATGL, 270–271
- ATL2, 214
- ATL3, 212, 214–215, 217
- Atlastin, 304, 319
- ATP13A1, 61, 64
- Autophagy. *See* ER-phagy; Lipid transport to isolation membrane

Index

B

BACE, 105
BAG6, 60
Bag6, 46
BBF2H7, 132–135
Behçet disease, 102
BiP
 ADP-ribosylation, 143
 AMPylation
 discovery, 142–144
 enzyme. *See* FICD
 functional consequences, 144–147
 prospects for study, 156–157
 endoplasmic reticulum proteostasis, 141–142
BPAN, 251
Brachyury, 133
BSC2L, 268

C

C53, 212, 214–215, 220
CALCOCO1, 212, 214–215
Calmodulin (CaM), 46, 50
CaM. *See* Calmodulin
CaMKII, 325
CAMK2B, 215
CAML, 48
CCDC47, 9, 28–31
CCPG1, 212, 214–215, 217, 219
CCT, 237
Cdc48, 75, 79–81, 98
CDS1, 265
CDS2, 265
Cerebellar ataxia, 251
CFNC. *See* Cytoplasmic filament nucleoporin complex
CFTR, 86
CGI-58, 271
ChAc. *See* Chorea-acanthocytosis
Charcot–Marie–Tooth disease, 104
Cholesterol transport
 accessibility of cholesterol, 278–280
 ASTER proteins
 Aster-B transcriptional regulation by
 LXRs, 282
 ASTER domain, 280–281
 GRAM domain, 281–282
 High-density lipoprotein-cholesterol transport to
 endoplasmic reticulum, 285–286
 Low-density lipoprotein-cholesterol transport to
 endoplasmic reticulum, 283–285
 overview, 277–278
 plasma membrane cholesterol
 fate

 esterification, 286
 oxysterol production, 286
 transport from endoplasmic reticulum, 287–288
 prospects for study, 288
CHOP, 130, 324
Chorea-acanthocytosis (ChAc), 247, 249
CHP-1, 264
ChREBP, 262
Chylomicron retention disease (CMRD), 199–200
CIDE-B, 202, 271
Cis1, 64
CLIMP63, 301, 307
Climp-63, 317–318, 324
CMRD. *See* Chylomicron retention disease
CMV. *See* Cytomegalovirus
CnC-C, 161–162
CNT, 337
Collagen type VIII, 134
COPI, 176
COPII, 134–135, 195–197, 286
 bulky cargo adaptation
 export structures, 183–184
 overview, 180–181
 TANGO1
 endoplasmic reticulum exit, 183
 mechanism of function, 181–183
 requirement, 181
 cargo capture by receptors, 178–180
 diseases, 186–187
 export regulation, 186
 lipoprotein export. *See* Apolipoprotein B; SURF4
 overview, 176–177, 195–197
 post-translational modifications of proteins, 185
 prospects for study, 187
 vesicle formation, 177–178
CRL3, 180
cTAGE5, 181–183, 203
CUL3, 180
Cyb5, 42
CyoA, 27
CYP27A1, 287
CYP27B1, 287
CYP51A1, 66, 86
Cytidine diphosphate-diacylglycerol pathway, 262, 265
CYTOLD, 270
Cytomegalovirus (CMV), 86
Cytoplasmic filament nucleoporin complex
 (CFNC), 340

D

Dbp5, 343
DDI-1, 165

- Ddi1, 165
DDI2, 165, 168–169
DDRKG1, 215, 220
DDX19, 340, 343
Decatransin, 11–12
Derlin
 cancer progression role, 101
 endoplasmic reticulum–associated degradation
 functions, 97–99
 physiological roles, 100–101
 protein quality control functions, 99–100
Derlin-1, 75, 80, 83, 86, 97–100
Derlin-2, 97, 99–101
Derlin-3, 97, 99, 101
Dfm1, 80, 98–99
DGAT1, 266–267
DGAT2, 83, 267–268
DHCR24, 85
Diabetes, 316
Doa10, 64–65, 67, 80–82, 84
DP1, 300–301, 307, 319
Dsc2, endosome Golgi–associated degradation
 role, 101–102
Dsk2, 80
- E**
- Ebola virus, 347
EGAD. *See* Endosome Golgi–associated degradation
EGFR, 103–104
eIF2 α , 127
ELYS, 340
EMC1, 50
EMC2, 47
EMC3, 24, 26, 29–31, 42, 47–50
EMC4, 49–50
EMC5, 47
EMC6, 31, 47–50
EMC7, 49–50
EMC8, 43, 47
EMC9, 43
Endoplasmic reticulum–associated degradation
 (ERAD)
 Derlin functions, 97–99
 HMGCR. *See* HMG-CoA reductase
 mammalian branches
 AMFR, 83
 HRD1, 81
 overview, 83
 RNF5, 86
 RNF139, 85–86
 RNF145, 86
 RNF170, 87
 RNF185, 86–87
 substrates, 76–78
 TEB4, 83–85
 TMEM129, 87
 nascent protein localization role
 Asi complex mediation, 65–66
 Doa10 in quality control, 65
 overview, 64–65
 prospects for study, 66
 Nrf1, 163, 165
 overview, 73–74, 95–97
 UBAC2 functions, 102
 yeast branches
 Asi complex, 82–83
 Doa10 complex, 80–82
 Hrd1 complex, 75, 79–80
 substrates, 76
Endoplasmic reticulum exit site (ERES), 176–177,
 180–182, 186–187, 227, 229, 237
Endoplasmic reticulum structure
 architecture, 296–298
 cytoskeleton linkers, 297–298
 electron microscopy
 cisternae and fenestrated sheets, 307–308
 matrices, 305–306
 nanostructure overview, 298–300
 nuclear envelope sheets and junctions, 308
 sheets
 overview, 306
 stacked helicoidal sheets, 306–307
 twisted sheets, 306–307
 three-way junctions, 303–305
 tubules, 300–303
 history of study, 295–297
 obesity effects, 322–325
 starvation effects, 320, 322
 subdomains and functions
 membrane contact sites, 319–321
 overview, 316–317
 sheets, 317–319
 tubules, 319
Endosome Golgi–associated degradation (EGAD),
 Dsc2 role, 101–102
ERAD. *See* Endoplasmic reticulum–associated
 degradation
ERES. *See* Endoplasmic reticulum exit site
Erg1, 81, 84
Erg11, 66
ERGIC, 177–178, 180, 184, 186
ERGIC53, 177–179
ERK1, 167
ERK2, 167
ERLIN, 87

Index

- Erlin1, 66
Erlin2, 66
ERMES, 247
ER-phagy
 classification, 212
 history of study, 211
 macro-ER-phagy
 autophagosome recognition of endoplasmic reticulum, 212–217
 physiological roles
 misfolded protein elimination, 217–219
 nuclear membrane degradation, 220
 principles, 217
 stalled nascent polypeptide removal, 219–220
 micro-ER-phagy, 220–221
 prospects for study, 221
ERPHS, 219
ERSE, 128
ERTOLD, 270
Erv14, 203
Erv24, 203
Erv29, 200
ESCRT, 212, 221
- F**
- FAM134A, 212, 215, 217–218
FAM134B, 212, 214–215, 217–219
FAM134C, 212, 215, 217–218
FAM8A1, 85
FAPP2, 245
FICD
 AMPylation and deAMPylation activity, 147–148
 BiP AMPylation regulation
 allosteric regulation, 148–150
 substrate-level regulation, 148
 discovery, 143–144
 fitness benefits and conservation, 152–156
 monomer/dimer equilibrium regulation by ATP/ADP ratio, 150–152
 prospects for study, 156–157
FIP200, 214
Fpp, 117
Frizzled-6, 102
- G**
- GABARAP, 214, 217
GADD34, 130
GET1, 60
Get1, 9, 24, 30, 40, 42–43, 45, 47–49
GET2, 60
Get2, 9, 40, 42–43, 45, 47–49
GET3, 60
Get3, 42, 44–47
Get4, 42, 60
Get5, 42
GGpp, 115–119
GLE1, 340, 343–344, 346
GLUT1, 101
GM130, 183
Gp78, 83, 102
GPAT1, 264
GPAT3, 263–264
GPAT4, 263–264, 269
GRAMD1B, 288
GRP78, 24
- H**
- HAC1, 129–131, 136
HAX-1, 325
HBV. *See* Hepatitis B virus
HDL. *See* High-density lipoprotein
HDL2, 249
Hepatitis B virus (HBV), 347
Hereditary spastic paraplegia (HSP), 242
High-density lipoprotein (HDL), cholesterol transport to endoplasmic reticulum, 285–286
HIV. *See* Human immunodeficiency virus
Hmg2, 81
Hmg2p, 115
HMG-CoA reductase (HMGCR), 66, 80, 86, 96, 281
 endoplasmic reticulum–associated degradation
 GGpp target identification, 116–118
 prospects for study, 120–121
 UBIAD1 regulation and physiological significance, 118–120
 ubiquitination and acceleration, 113–116
 functional overview, 111–113
 structure, 113
HMGCR. *See* HMG-CoA reductase
HO-1, 85
HOXA9, 344
HRD1, 66, 81
Hrd1, 50, 65–66, 96, 98
Hrd1 complex, 75, 79–80
Hrd3, 75, 98
HRV. *See* Human rhinovirus
HSD17B13, 270
HSL, 271
HSP. *See* Hereditary spastic paraplegia
HSP47, 181
Hsp70, 141–142
HSV-1, 103

Human immunodeficiency virus (HIV), 347
Human rhinovirus (HRV), 347
Hypercholesterolemia, 199–200

I

IbpA, 143
Influenza A, 347
INSIG1, 286–287
IP3R, 324–325
Ipomoeassin F, 11
IRE1, 324
 downstream transcription factors in
 metazoans, 131
 isoforms, 129
 knockout studies, 132
 mRNA decay regulation, 135–137
 unfolded protein response pathway, 128–130
iRhom
 cancer role, 103
 endoplasmic reticulum–associated degradation
 functions, 102–103
 RHBDL4 functions, 103–104
 structure, 102
Isolation membrane. *See* Lipid transport to isolation
 membrane
Iterative insertion model, multipass proteins, 26–29

J

JNK, 135, 324
JPH3, 249

K

Kar2, 75
Kennedy pathway, glycerolipid synthesis in endoplasmic
 reticulum, 262–266
KLHL12, 203
KTN, 307
KTN1, 317

L

Lamin B1, 220
LAP1, 198
LC3, 221
LD. *See* Lipid droplet
LDAF1, 270
Ldb16, 269
LDL. *See* Low-density lipoprotein
LDLR, 199
Lipid droplet (LD), synthesis in endoplasmic reticulum,
 268–271, 319
Lipid transport to isolation membrane

ATG2
 lipid specificity, 229
 structural basis of lipid transfer, 230–232
 transfer rates of lipids, 229–230
Atg9-mediated lipid scrambling, 232–234
autophagy overview, 227–228
bulk lipid delivery between organelles, 228–229
phospholipid distribution to endoplasmic reticulum
 leaflets, 234–236
phospholipid distribution to isolation membrane
 leaflets, 232
prospects for study, 237–238
unidirectional lipid transfer mechanism from
 endoplasmic reticulum to isolation
 membrane, 236–237
Liver X receptors (LXRs), 279, 282, 288
LMBR1L, 102
Lnp1, 219
Low-density lipoprotein (LDL), cholesterol transport to
 endoplasmic reticulum, 283–285

LPCAT3, 198

LptA, 236
LptB, 236
LptC, 236
LptD, 236–237
LptG, 236
LTK, 186
LXRs. *See* Liver X receptors

M

Macro-ER-phagy. *See* ER-phagy
Maf, 162
MARCH6, 65–66
MARCHF6, 81, 83–85
Mata2, 80
MBOAT, 265–266
MBRL, 66, 86–87
MCS. *See* Membrane contact site
Membrane contact site (MCS)
 electron microscopy, 242
 functional overview, 243
 lipid transfer proteins, 243
 neurodegeneration and dysfunction
 amyotrophic lateral sclerosis, 244–246
 cerebellar ataxia, 251
 chorea-acanthocytosis, 247, 249
 overview, 243–244
 Parkinson's disease, 249–250
 spinocerebellar ataxia, 250
 VPS13 proteins and neurodegeneration,
 246–251
 prospects for study, 252
 structure and function, 319–321

Index

- Mevalonate pathway, 112
- MIA, 181
- MIA2, 181
- Mia2, 203
- MIA3. *See* TANGO1
- Micro-ER-phagy. *See* ER-phagy
- Miro1, 250
- Miro2, 250
- MK-4, 119
- MK-7, 119
- MK-9, 119
- MK-11, 119
- MPZ, 105
- MsbA, 234
- Msp1, 61, 63, 67
- mTORC1, 167
- MTP, 198, 271
- Multipass proteins. *See also specific proteins*
- biogenesis initiation
 - insertion mechanisms, 22
 - type I membrane proteins, 23
 - type II membrane proteins, 23
 - type III membrane proteins, 23–24
 - biogenesis model, 30–32
 - chaperones, 29–30
 - iterative insertion model, 26–29
 - overview, 19–21
 - topology determinants, 25–26
 - translocon, 30
- Mycolactone, 11
- N**
- NAC. *See* Nascent polypeptide–associated complex
- NAFLD. *See* Nonalcoholic fatty liver disease
- Nascent polypeptide–associated complex (NAC), 59–60, 67
- Nascent protein localization
- cotranslational protein targeting
 - signal recognition particle–independent targeting, 59
 - signal recognition particle–mediated targeting, 58–60
 - endoplasmic reticulum–associated degradation role
 - Asi complex mediation, 65–66
 - Doa10 in quality control, 65
 - overview, 64–65
 - prospects for study, 66
 - overview, 57–58
 - prospects for study, 66–67
 - tail-anchored protein localization
 - dislocases and maintenance of localization, 61–62
 - overview, 60
 - protein selection for endoplasmic reticulum insertion, 60–61
 - quality control, 62–64
- NDC1, 340, 342
- NE. *See* Nuclear envelope
- NFE2, 162
- NFE2L1, 316
- NGLY1, 165–166, 168
- Niemann–Pick disease, 246, 277
- Nir2, 245
- Nir3, 245
- Nonalcoholic fatty liver disease (NAFLD), 267, 270
- NPC. *See* Nuclear pore complex
- NPC1, 246, 277, 283–285
- NPC2, 246, 277, 283
- Nrf1
- deglycosylation-dependent sequence editing, 165–167
 - evolution of NRF transcription factors, 162
 - overview, 161–162
 - physiological roles
 - cancer, 168
 - lipid and cholesterol metabolism, 169
 - proteasome regulation, 167–168
 - prospects for study, 169
 - proteolytic activation, 165
 - synthesis and degradation, 163–165
- Nrf2, 162
- Nrf3, 162
- Nuclear envelope (NE), sheets and endoplasmic reticulum junctions, 308
- Nuclear pore complex (NPC)
- cytoplasmic filament nucleoporin complex, 340
 - dilation and lateral channel formation, 338–340
 - functional overview, 333–334
 - mRNA transport, 342–344
 - nucleoporin diseases, 344–346
 - prospects for study, 347
 - structure
 - bridge between rings, 338
 - channel, 337–338
 - cytoplasmic face architecture, 340–341, 343
 - history of study, 334, 336
 - inner ring, 336–337
 - linker scaffold, 335
 - outer ring, 336
 - virus targeting, 346–347
- NUP37, 344
- NUP42, 337, 340, 343–344
- NUP50, 337, 340
- NUP53, 336
- NUP54, 336–337

NUP58, 336–337
NUP62, 336–337, 340
NUP88, 340, 344
NUP93, 336–338, 344
NUP98, 336, 340, 344
NUP98, 344
NUP107, 338
NUP133, 338, 340
NUP153, 337, 340
NUP155, 336–338, 340
NUP160, 338, 344
NUP188, 336–337
NUP205, 336–338, 344
NUP214, 337, 340
NUP214, 344
NUP358, 337, 340, 344, 346

O

Obesity, effects on endoplasmic reticulum
architecture and organization, 322–324
inter-organelle contact sites, 324–326
Oligosaccharyltransferase complex, 2, 10, 30
OlyA, 279
Ora1, 243
Orm2, 101–102
ORP1L, 245, 284
ORP2, 284
ORP5, 284
OSBP1L, 284, 287
OSBPL2, 284
OSBPL5, 284
OST-A, 11
OST-B, 11
OTOR, 181
Oxa1, 1, 9, 19–21, 24–25, 29, 32, 42, 47

P

P5A-ATPase, 61–62, 64, 67
p24, 179
p62, 212
p125A, 184
p180, 307
PACS-2, 324, 326
PARK23, 249
Parkin, 250
Parkinson's disease (PD), 246, 249–250
PAT complex, 9–10, 28, 30–32
PC1, 197
Pca1, 81
PCSK9, 199
PD. *See* Parkinson's disease
PDI, 198

PDP1, 118
PDZD8, 245
PEF1, 186
PERK
advent in metazoans, 131
knockout studies, 132–133
unfolded protein response pathway, 130
Pex15, 61–63
PEX29, 270
PEX30, 270
Pex30, 269
PFO, 278
PGRMC1, 218
Phospholipid, synthesis in endoplasmic reticulum,
262–266

PI3P, 228, 232
PINK1, 250
PKAN2, 249
PLAAT, 221
PLTP, 198
PNG-1, 165–166, 168
PNPLA3, 270
Poliovirus, 347
POM121, 340, 343
POM210, 340, 343
POMC, 218
Protein localization. *See* Nascent protein localization
pTAC, 303
PtdSer, 244
PTP1P51, 246

R

Rab1, 179
Rad23, 80
RAE1, 340, 343–344, 347
RAMP4, 85
RanGAP, 340
RAT8, 343
REEP, 300–301, 307
REEP5, 319, 323
RHBDL4, 324
Alzheimer's disease role, 105
cancer studies, 104
endoplasmic reticulum–associated degradation
functions, 103–104
physiological roles, 104
structure, 103
Rhomboid protease. *See* RHBDL4
Rhomboid pseudoproteases. *See* Derlin; Dsc2; iRhom;
UBAC2
Ribosome–nascent chain complex, 2–3, 9, 58
RIDD, 136–137

Index

- RIGI*, 137
RNF5, 86
RNF126, 45, 65
RNF139, 65–66, 85–86
RNF170, 87
RNF185, 66, 86–87
RPN1, 10
RPN4, 162
RRBP1, 317–318
RTN3, 218–219
RTN3L, 212, 214–215, 218–219
Rtn4, 323
- S**
- S1B, 131
SAR1, 196–197, 199
Sar1, 177
SAR1B, 204
Sar1B, 271
SARS, 347
SCAP, 279, 286–288
SCAR20, 251
SEC12, 196
Sec12, 177, 181–182
SEC13, 196
Sec16, 177
Sec23, 134, 177–178, 181, 196
SEC23A, 184
Sec23B, 187
SEC24, 196
Sec24, 134–135, 177–178
SEC24C, 219
SEC31, 196
Sec31, 177
SEC61, 197, 219
SEC61 α , 59
Sec61 complex
 accessory factors, 11
 architecture, 4–5, 21
 channel gating
 cotranslational translocation, 6
 coupling of central pore and lateral gate, 5–6
 post-translational translocation, 6–8
 cotranslocational *N*-glycosylation and signal
 sequence cleavage, 10–11
 inhibitors, 11–12, 26
 membrane protein integration, 8–10
 overview, 1–2, 19–20
 prospects for study, 12
 protein targeting, 2–4
SEC62, 59, 212, 215, 217, 219
Sec62, 2–4, 6–7
Sec63, 2–4, 6–7, 59
SEC71, 59
SEC72, 59
SecA, 4
SecG, 4
SecY complex
 architecture, 4–5
 crystal structure, 2
 overview, 1–2, 20
Sed5, 179
Sendai virus, 103
SERCA, 324, 326
Sey1p, 304
SFT-4, 200
Sgt2, 42, 45, 60
SGTA, 45, 50, 60
Sheet. *See* Endoplasmic reticulum structure
SHIP164, 251
Signal peptide peptidase (SPP), 65, 85–86
Signal recognition particle (SRP), 2–3, 19, 24, 27, 40, 42,
 59–61, 67, 318
SKN-1A
 deglycosylation-dependent sequence editing,
 165–167
 evolution of NRF transcription factors, 162
 overview, 161–162
 physiological roles
 cancer, 168
 lipid and cholesterol metabolism, 169
 proteasome regulation, 167–168
 prospects for study, 169
 proteolytic activation, 165
 synthesis and degradation, 163–165
SNX2, 246
SNX13, 251
SNX14, 251
SNX19, 251
SNX25, 251
SOAT1, 268
SOAT2, 268
SOCE, 320, 326
Spastin, 304
Spf1, 61–63
Spinocerebellar ataxia, 250
SPP. *See* Signal peptide peptidase
Squalene monooxygenase, 84–85
SR. *See* SRP receptor
SR α , 3
SR-B1, 285
SREBP, 101, 114, 116
SREBP-1c, 262, 282
SREBP-2, 100, 278–279, 281–282, 285–286, 288, 316
SRNS. *See* Steroid-resistant nephrotic syndrome

- SRP receptor (SR), 23, 58
SRP. *See* Signal recognition particle
SRP54, 3, 59
STARD1, 277
STARD3, 245, 287
STARD11, 245
Starvation, effects on endoplasmic reticulum structure and function, 320, 322
Ste6, 80
Ste24, 220
Steroid-resistant nephrotic syndrome (SRNS), 344
Sterol esters, synthesis in endoplasmic reticulum, 268
STIM, 326
STIM1, 243, 303, 326
STING, 103, 200, 250
STT3, 10–11
STX17, 221
SUMO4, 102
SURF4
 cargo receptor
 complex
 auxiliary cofactors, 203
 enzymes, 201–202
 overview, 199
 isoforms, 197
 lipoprotein secretion role, 200–201
 prospects for study, 203–204
SYVN1, 66, 83
- T**
- TACE, 103
Tail-anchored (TA) protein
 biogenesis, 40–41
 handover and capture by insertases, 46–47
 lipid bilayer insertion, 47–50
 nascent protein localization
 dislocases and maintenance of localization, 61–62
 overview, 60
 protein selection for endoplasmic reticulum insertion, 60–61
 quality control, 62–64
 overview, 39–40
 prospects for study, 50–51
 targeting
 cytosolic targeting, 44–46
 pathway discovery, 41–44
TAL1, 181, 203
TAMM41, 265
TANGO1, 181–183
Tango1, 135
TAOK2, 303
TA protein. *See* Tail-anchored protein
TEB4, 65, 81, 83–85
TEX264, 212, 214–215, 217
TFEB, 249
TFG, 177, 184
TGH, 271
TM6SF2, 202, 271
TMCO1, 9–10, 24, 30–31, 42
TMEM41B, 198, 201, 235–237, 251
TMEM129, 86–87
TMEM131, 184
TMUB1, 66, 86
TMUB2, 66, 86
TorsinA, 198
TPR, 337, 340
TPR, 344
TRAF2, 135
TRAM, 11, 29
TRAP, 11
TRC8, 85–86
TRC35, 45
TRC40, 42, 45–46
Triglyceride, synthesis in endoplasmic reticulum, 266–268
TRIM13, 215, 218
Tubule. *See* Endoplasmic reticulum structure
Tvp38, 235
- U**
- U18666A, 280–281
UBAC2, 83
 Behçet disease role, 102
 endoplasmic reticulum–associated degradation functions, 102
 iRhom role, 102–103
UBASH3B, 102
Ubc6, 65, 81–82
Ubc7, 65, 79, 82
UBE2G2, 83, 85–86
UBE2J2, 82, 85, 87
UBE2K, 86–87
UBEQL1, 102
UBIAD1, 116, 118–121
Ubiad1, 118–120
UBL4A, 45, 60
Ubp1, 79
Ubx2, 75
Ufd2, 80
UFL1, 215, 220
UGGT1, 218
UHRF1BP1, 251
ULK1, 214, 218, 221
ULK2, 218, 221

Index

- Unfolded protein response (UPR)
 changes in evolution
 ATF6-like factors in vertebrates, 132
 downstream transcription factors from IRE1 in metazoans, 131
 PERK advent in metazoans, 131
 regulator chaperones in vertebrates, 131–132
 IRE1-dependent decay of mRNA, 135–137
 overview, 127–128, 315–316
 pathways
 ATF6, 130–131
 IRE1, 128–130
 knockout studies
 ATF6 pathway, 133
 BBF2H7 pathway, 133–135
 IRE1 pathway, 132
 PERK pathway, 132–133
 PERK, 130
 prospects for study, 137
 UPR. *See* Unfolded protein response
UPS20, 46
UPS33, 46
US11, 86
Usa1, 75, 80
- V**
Vac8, 220
VAMP8, 218, 221
VAP, 244–246
VAP-A, 214–215, 244, 246
- VAP-B, 214–215, 244, 246
VISA, 103
Vitellogenin, 270
VMP1, 201, 235–237
VMP1, 250–251
VopS, 143
Vps13, 219, 230, 246–247
VPS13A, 245–247, 249
VPS13B, 247
VPS13C, 245, 247, 249–250
VPS13D, 246–247, 250–251
VSV, 103, 347
- W**
WDR45, 251
WIPI4, 229, 251
WIPI12, 214
WNT, 102
- X**
XBP1, 129–132, 136
XK, 249
XKr8, 249
- Y**
YidC, 1, 9, 24, 27, 29, 32, 42, 50
Ylp1, 42
Yop1p, 300–301, 307
Yos9, 75